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Letter to the Editor 
Restless legs syndrome and mortality in hemodialysis patients  
 
 
To the Editor: 
We thank Elias et al. for their concerns regarding our findings [1] of missing association between 
Restless Legs Syndrome (RLS) and mortality in hemodialysis, contradicting previous survival studies 
[2,3]. However, there was agreement on RLS prevalence between our study (26.6%) and the studies 
by La Manna et al. (31%) and Lin et al. (25%) [1–3]. 
We agree that predictors of RLS in hemodialysis may also influence mortality and might have 
confounded survival analyses so 
far. In our study RLS hemodialysis patients were younger than those without RLS [1]. However, RLS 
patients had higher diabetes prevalence in the study by Lin et al. [3], while patients had lower 
frequency of rest-diuresis >500 ml/d in the study La Manna et al.[2]. Age, diabetes, and missing rest-
diuresis are all indubitably strong mortality predictors. While of course adjustments for confounders 
were done, whether in our study or in past studies, confounding bias might not be abolished, even 
with properly planned multivariate analysis. Serum intact parathormone (iPTH) and phosphorus, 
predicting uremic RLS in our study, were not associated with mortality in either univariate or 
multivariate analyses. These negative findings remained, whether iPTH and phosphorus were 
examined in different multivariate models or in subgroup analyses, ie, subgroups with high 
(>150 ng/ml) or low iPTH (<150 ng/ml). 
Furthermore, investigating prevalent cases [1–3] using a crosssectional design may lead to significant 
survivor bias. In the only previous survival report [4] that investigated incident hemodialysis patients, 
RLS screeningwas not based on the international criteria and might have had limited reliability [5]. 
The above facts, along with the high probability of publication bias [1] and lack of power in some 
reports [2], implicate a rigorous need for more prospective investigations of mortality risk in uremic 
RLS. 
  
Conflict of interest 
None. 
 
References 
[1] Stefanidis I, Vainas A, Giannaki CD, et al. Restless legs syndrome does not affect 
3-year mortality in hemodialysis patients. Sleep Med 2015;16:1131–8. 
[2] La Manna G, Pizza F, Persici E, et al. Restless legs syndrome enhances 
cardiovascular risk and mortality in patients with end-stage kidney disease 
undergoing long-term haemodialysis treatment. Nephrol Dial Transplant 
2011;26:1976–83. 
[3] Lin CH, Sy HN, Chang HW, et al. Restless legs syndrome is associated with 
cardio/cerebrovascular events and mortality in end-stage renal disease. Eur J 
Neurol 2015;22:142–9. 
[4] Unruh ML, Levey AS, D’Ambrosio C, et al. Restless legs symptoms among incident 
dialysis patients: association with lower quality of life and shorter survival. Am 
J Kidney Dis 2004;43:900–9. 
[5] Cirignotta F, Mondini S, Santoro A, et al. Reliability of a questionnaire screening 
restless legs syndrome in patients on chronic dialysis. Am J Kidney Dis 
2002;40:302–6. 
 
Authors & Affiliations:  
I. Stefanidis *, A. Vainas 
Department of Nephrology, School of Medicine, University 
of Thessaly, Larissa, Greece 
C.D. Giannaki 
Department of Life and Health Sciences, University of Nicosia, 
Cyprus, Greece 
E. Dardiotis 
Department of Neurology, School of Medicine, University 
of Thessaly, Larissa, Greece 
A. Spanoulis, M. Sounidaki, T. Eleftheriadis, V. Liakopoulos 
Department of Nephrology, School of Medicine, University 
of Thessaly, Larissa, Greece 
C. Karatzaferi, G.K. Sakkas 
School of Physical Education and Sport Science, University 
of Thessaly, Trikala, Greece 
E. Zintzaras 
Department of Biomathematics, School of Medicine, University of 
Thessaly, Larissa, Greece 
Institute for Clinical Research and Health Policy Studies, Tufts 
University School of Medicine, Boston, MA, USA 
G.M. Hadjigeorgiou 
Department of Neurology, School of Medicine, University 
of Thessaly, Larissa, Greece 
* Address: School of Medicine, University of Thessaly, 
Panepistimiou str. 3, 41500 Larissa, Greece. 
Tel.: +30 2413501667 8; fax: +30 2413501667. 
E-mail address: stefanid@med.uth.gr (I. Stefanidis) 
 
